FREDERICK, Md., Sept. 27, 2023 (GLOBE NEWSWIRE) — TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ: TOMZ), a global company specializing in disinfection and decontamination solutions, today announced that it has partnered with Colcom, Inc. to offer SteraMist iHP products as part of Colcom’s life sciences and healthcare portfolio of products.
With a combined 50 years of technical sales expertise, Colcom, Inc. has joined forces with TOMI under the leadership of Bridget Collins. Established in 1970, Colcom, Inc. is a trusted supplier of high-quality clinical and laboratory equipment. Given its established customer base and extensive expertise in the decontamination industry, this partnership will be mutually advantageous.
Bridget Collins, President of Colcom, Inc., states, “Colcom, Inc. takes great pride in offering SteraMist products alongside our top-tier solutions for the clinical and laboratory sectors. Experienced in the decontamination field, we found SteraMist technology to be superior and believe this collaboration seamlessly aligns with the needs of many of our current customers. We look forward to partnering with TOMI and delivering SteraMist products to our community.”
“We are proud to announce Colcom, Inc. as a sales partner and greatly look forward to working together. Bridget’s extensive expertise in decontamination will serve as a catalyst for our continued expansion within the life science and healthcare sectors,” states E.J. Shane, COO of TOMI.
Learn more about Colcom, Inc. here.
TOMI™ Environmental Solutions, Inc.: Innovating for a safer world®
TOMI™ Environmental Solutions, Inc. (NASDAQ: TOMZ) is a global decontamination and infection prevention company, providing environmental solutions for disinfection through the manufacturing, sales and licensing of its premier Binary Ionization Technology ® (BIT™) platform. Invented under a defense grant in association with the Defense Advanced Research Projects Agency (DARPA) of the U.S. Department of Defense, BIT™ solution utilizes a low percentage hydrogen peroxide as its only active ingredient and uses patented ionized Hydrogen Peroxide (iHP™) technology in all SteraMist systems to create superior disinfection. TOMI products are designed to service a broad spectrum of use sites, including, but not limited to, hospitals and medical facilities, biosafety labs, pharmaceutical facilities, commercial and office buildings, schools, restaurants, meat and produce processing facilities, and police and fire departments.
For additional information, please visit https://steramist.com/ or contact us at info@tomimist.com
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995
This press release contains forward-looking statements that are based on current expectations, estimates, forecasts and projections of future performance based on management’s judgment, beliefs, current trends, and anticipated product performance. These forward-looking statements include, without limitation, statements relating to partnership with Colcom, Inc.. Forward-looking statements involve risks and uncertainties that may cause actual results to differ materially from those contained in the forward-looking statements. Forward-looking statements involve a number of risks and uncertainties, all of which are difficult or impossible to predict accurately and many of which are beyond our control. As such, our actual results could differ materially and adversely from those expressed in any forward-looking statements as a result of various factors. Important factors that could affect our performance and cause results to differ materially from management’s expectations are described in the section entitled “Risk Factors,” in our Annual Report on Form 10-K and other SEC filings. These factors include: our history of losses that may prevent us from achieving profitability in the future; our lack of long-term customer contracts and our inability to rely on our sales history or backlog as an indicator of our future sales; that we are subject to a variety or risks associated with doing business internationally; our success in business depends on our ability to adequately protect our intellectual property; and that our stock price is volatile and there is a limited market for our shares. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, level of activity, performance, or achievements. You should not place undue reliance on these forward-looking statements. All information provided in this press release is as of today’s date, unless otherwise stated, and we undertake no duty to update such information, except as required under applicable law.
INVESTOR RELATIONS CONTACT:
John Nesbett/Rosalyn Christian
IMS Investor Relations
FRONTIER2 data presented at ISTH 2024 showed that up to 95% of people, who had…
Pemvidutide elicited significant weight loss and decreases in pro-inflammatory serum lipids associated with atherogenesis and…
TAIPEI, June 22, 2024 /PRNewswire/ -- The prestigious 2024 Tang Prize Laureates have been announced,…
Afrezza® Afrezza® (insulin human) Inhalation Powder. Study proves inhaled insulin is as effective as usual…
PURCHASE, NY, June 21, 2024 (GLOBE NEWSWIRE) -- Teladoc Health (NYSE: TDOC), the global leader…
TERN-501 significantly improved the efficacy of a GLP-1 receptor agonist by normalizing energy expenditure, resulting…